Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuFYFan YangLMLixia Ma

Discussion

Loading...

Member takes

Overview

Prospective study demonstrates therapeutic potential of CD19 CAR-T, improving clinical outcomes in highly refractory CNS lymphoma patients, indicating manageable adverse events.

Key Points

  • Evaluate safety and efficacy of CD19 CAR-T therapy in patients with relapsed/refractory CNS lymphoma.
  • Prospective phase I/II clinical trial at a single center
  • 6 patients received CAR-T cells with stepwise infusions
  • Dose escalation was evaluated using a standard 3+3 design
  • Safety endpoints included adverse events and serious adverse events
  • Overall response and survival rates were calculated using Kaplan-Meier method.
  • 45 patients infused with CD19 CAR-T cells
  • Overall response rate was 75.6% and complete response rate was 66.7%
  • Median progression-free survival was 20.12 months
  • Cytokine release syndrome occurred in 53.3% of patients, with manageable severity
  • CAR-T cells were transported to CNS and expanded in cerebrospinal fluid.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8cdhttps://doi.org/10.1182/blood-2025-672
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of CD-19–directed CAR-T therapy in patients with primary and secondary central nervous system lymphoma: A multi-center observational study.2026
  2. 2Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells2024 · 10 citations
  3. 3P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  4. 4CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC network2024 · 66 citations
  5. 5Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma2025